Allogene Therapeutics (ALLO)

• Market cap: $666M
• 1 day: -3.5%
• 5 days: -8.1%
• 1 month: -0.52%
• 3 months: -36.93%
• 6 months: 17.68%
• Year to date: 42.96%
• 1 year: 49.61%
• 5 years: -91.62%
• 10 years: -92.28%
• Sector: Healthcare
• Industry: Biotechnology

About: Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).

Employees: 152